Herein, we conducted a retrospective cohort study to investigate whether LCT combined with PD-1/PD-L1 inhibitor is a promising first-line strategy for oligo-residual advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.